Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777247 | 0.88 | MTNR1A (0.40) | MTNR1AMTNR1BRORCMIFLTB4R | |
| SCHEMBL21787275 | 0.75 | MTNR1A (0.39) | MTNR1AMTNR1BRORCMIFAKR1B1 | |
| SCHEMBL21787270 | 0.75 | MTNR1A (0.39) | MTNR1AMTNR1BRORCMIFAKR1B1 | |
| SCHEMBL21777337 | 0.74 | KDM4D (0.31) | KDM4D | |
| SCHEMBL21777224 | 0.71 | RORC (0.35) | MTNR1AMTNR1BRORC | |
| SCHEMBL21777227 | 0.70 | MTNR1A (0.40) | MTNR1AMTNR1BRORCMIF | |
| SCHEMBL21777226 | 0.68 | — | — | |
| SCHEMBL19507346 | 0.68 | MTNR1A (0.50) | MTNR1AMTNR1BRORCMIFGPR119 | |
| SCHEMBL25972059 | 0.67 | MTNR1A (0.56) | MTNR1AMTNR1BRORCGPR119 | |
| SCHEMBL31583240 | 0.66 | MTNR1A (0.43) | MTNR1AMTNR1BRORCMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843728-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-3843728-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020047207-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047207-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | MTNR1A 3157/4885MTNR1B 2099/4885RORC 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.